HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
HER-2/neu (neu-N) transgenic mice, which express the nontransforming rat proto-oncogene, develop spontaneous focal mammary adenocarcinomas beginning at 5-6 months of age. The development and histology of these tumors bears a striking resemblance to what is seen in patients with breast cancer. We have characterized the immunological responses to HER-2/neu (neu) in this animal model. neu-positive tumor lines, which were derived from spontaneous tumors that formed in neu-N animals, are highly immunogenic in parental, FVB/N mice. In contrast, a 100-fold lower tumor challenge is sufficient for growth in 100% of transgenic animals. Despite significant tolerance to the transgene, neu-specific immune responses similar to those observed in breast cancer patients can be demonstrated in neu-N mice prior to vaccination. Both cellular and humoral neu-specific responses in transgenic mice can be boosted with neu-specific vaccination, although to a significantly lesser degree than what is observed in FVB/N mice, indicating that the T cells involved are less responsive than in the nontoleragenic parental strain. Using irradiated whole-cell and recombinant vaccinia virus vaccinations we are able to protect neu-N mice from a neu-expressing tumor challenge. T-cell depletion experiments demonstrated that the observed protection is T cell dependent. The vaccine-dependent neu-specific immune response is also sufficient to delay the onset of spontaneous tumor formation in these mice. These data suggest that, despite tolerance to neu in this transgenic model, it is possible to immunize neu-specific T cells to achieve neu-specific tumor rejection in vivo. These transgenic mice provide a spontaneous tumor model for identifying vaccine approaches potent enough to overcome mechanisms of immune tolerance that are likely to exist in patients with cancer.
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
R T
RT
Reilly
M B
MB
Gottlieb
A M
AM
Ercolini
J P
JP
Machiels
C E
CE
Kane
F I
FI
Okoye
W J
WJ
Muller
K H
KH
Dixon
E M
EM
Jaffee
D016475:3T3 Cells; D000230:Adenocarcinoma / Q000235:genetics* / Q000276:immunology* / Q000628:therapy; D000818:Animals; D019496:Cancer Vaccines; D005260:Female; D018734:Genes, erbB-2; D007108:Immune Tolerance; D008325:Mammary Neoplasms, Experimental / Q000235:genetics* / Q000276:immunology* / Q000628:therapy; D051379:Mice; D008815:Mice, Inbred Strains; D008822:Mice, Transgenic; D051381:Rats; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000276:immunology*; D013950:Thymus Gland / Q000276:immunology
D019496:Cancer Vaccines; D018719:Erb-b2 Receptor Tyrosine Kinases